MDRX heads into its May 1 Q1 results with shorts unwinding sharply and the stock posting its best week in months.
The most striking data point this week is not where short interest sits — it's how fast it moved. Short interest collapsed by more than 60% over the past week, falling from roughly 677,000 shares borrowed to just 265,000, cutting the estimated short interest to a mere 0.16% of the free float. A month ago that figure was closer to 0.33%. The retreat is dramatic. As recently as April 15, the ORTEX short score peaked at 50.4 — mid-range on the squeeze pressure scale. By April 28 it had dropped to 28.5, with the lending market confirming the story: borrow availability is now extremely loose, with utilisation barely above 1%. Cost to borrow has also fallen sharply — from peaks above 2.3% in mid-April, it now sits at 1.23%, down 20% on the week and 68% over the past month. Short sellers are not just covering; the infrastructure of a crowded short has essentially dissolved.
The stock itself has responded. Veradigm closed at $4.88 on April 28, up 12% on the day and 13% on the week. Year-to-date the gain narrows to just 1.7%, so context matters — the stock has spent most of 2026 going nowhere. What changed this week appears tied to the market sensing a better setup into the earnings print. Valuation remains genuinely compressed. The EV/EBITDA multiple sits near 3.3x. The earnings yield is running at 6.4%. The EV/EBIT score ranks in the 98th percentile of the universe — a signal that, relative to earnings power, the stock prices in very little optimism.
Analyst coverage on Veradigm is thin and the most recent changes are dated — the most recent available action is from Stephens & Co. in January 2025, which raised its target to $13 from $7 while keeping an Equal-Weight rating. The current mean price target of around $5.83 is modest above the current price and reflects a consensus of just one active buy recommendation. Given the gap between the stale analyst data and the current price, the Street's formal positioning should be treated as background context rather than a live signal. The ORTEX analyst return potential registers at 19.5% upside, and EPS momentum over the past 30 days ranks in the 88th percentile — meaning earnings estimate revisions have been positive heading into the May 1 print.
On the institutional side, the shareholder register features several active special-situation managers. Stonehill Capital holds 12.4% of shares. Madison Avenue Partners added more than 3.9 million shares in the last reported period, building to 4.2% of the company. Mason Capital Management initiated a position of roughly 6.3 million shares as of late January 2026. These are not passive holders — their presence suggests the stock has attracted investors with a view on a catalyst or restructuring outcome. A new CFO, Christian Greyenbuhl, was appointed on April 6, adding to the management transition backdrop ahead of results.
Looking at the last four earnings reactions, the pattern has been mixed but modestly negative on average. The most recent Q4 print in April saw a 1% one-day drop followed by a 10% five-day slide. The November 2025 report fell 3% on the day. The August 2025 report was the exception — up 4% on the day and 5% over five days. Peer TDOC was up 2.6% on the day and down 1.6% on the week, while OPRX dropped 11% over the same stretch, reflecting uneven sentiment across health-care technology names ahead of the reporting season.
The setup into May 1 is defined by unusually light short positioning, compressed valuation, and a wave of positive EPS estimate momentum — with five sessions of earnings history that lean slightly negative on the day but more variable over five days. What to watch is whether the first Q1 result under the new CFO, combined with thin institutional patience, produces a reaction that breaks the stock out of its year-to-date range.
See the live data behind this article on ORTEX.
Open MDRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
